Schaffner A
Universitätsspital Zürich, Labor für Makrophagenbiologie.
Ther Umsch. 2006 Mar;63(3):185-8. doi: 10.1024/0040-5930.63.3.185.
Fever is a phylogenetically ancient host reaction to invading microorganisms and other noxious stimuli. Poikylothermic organisms can reach febrile temperatures by seeking a hot environment in response to a higher set point in their thermoregulatory center. Endothermic organisms produce febrile temperatures through endogenous heat production at the expenditure of a higher metabolic rate. Nevertheless, fever has been conserved during evolution through millennia, obviously because of its advantage for host defense. Despite of these arguments most doctors, nurses and patients treat fever with antipyretics. The role of fever for the recovery from low risk infections is marginal at best. A large study of ibuprofen in patients with severe sepsis could not establish a positive or negative role on the course or final outcome of the infection in an intensive care setting. These clinical observations seemingly contradict findings in severe experimental bacterial infections in rodents but it has to be taken into consideration that these animals, in contrast to patients, received no antibiotic treatment. In patients with influenza-like illnesses non-steroidal antirhumatics (NSAR) improve fever and wellbeing with little or no evidence for undesired side-effects. It therefore appears appropriate to treat patients with these and similar infections with NSAR. Antipyretic therapy in special patient groups such as brain injury victims, patients with cardiac or respiratory failure or dementia has not been established to be indicated to overcome a worsening of these organs to fail during infections. In children with a history of fever convulsions prevention or lowering of fever does not reduce recurrence. In patients with strokes it appears advisable however to use antipyretics in case of fever despite of a present lack of a proven beneficial effect. In conclusion symptomatic antipyretic therapy should be considered for low risk infections if patient suffering from fever. For more severe infections antipyretic therapy can be applied on an individual basis without too much hope to improve outcome or cause a severe worsening of prognosis.
发热是机体对入侵微生物及其他有害刺激的一种在进化史上由来已久的宿主反应。变温动物可通过寻找炎热环境以应对其体温调节中枢设定点的升高,从而达到发热温度。恒温动物则通过提高代谢率产生内源性热量来达到发热温度。然而,历经数千年的进化,发热现象依然存在,显然是因为它对宿主防御具有优势。尽管有这些观点,但大多数医生、护士和患者仍使用退烧药来治疗发热。发热对低风险感染康复的作用充其量是微不足道的。一项针对严重脓毒症患者使用布洛芬的大型研究未能确定其在重症监护环境中对感染病程或最终结局的正面或负面作用。这些临床观察结果似乎与啮齿动物严重实验性细菌感染的研究结果相矛盾,但必须考虑到,与患者不同,这些动物未接受抗生素治疗。在患有流感样疾病的患者中,非甾体类抗炎药(NSAR)可改善发热症状并使患者感觉舒适,且几乎没有或没有不良副作用的证据。因此,用NSAR治疗这些及类似感染的患者似乎是合适的。对于特殊患者群体,如脑损伤患者、心脏或呼吸衰竭患者或痴呆患者,尚未确定使用退烧药可避免感染期间这些器官功能恶化。对于有发热惊厥史的儿童,预防或降低发热并不能减少复发。然而,对于中风患者,尽管目前尚无已证实的有益效果,但发热时使用退烧药似乎是可取的。总之,如果患者发热,对于低风险感染应考虑进行对症退热治疗。对于更严重的感染,退热治疗可根据个体情况应用,但不要寄希望于改善结局或导致预后严重恶化。